Specifically, ATAD3A, CALR, CWF19L1, GALT, MAGEA9, MAPKI8IP3, PSLNR, SEPTIN7P13, SLC19A1 and SLC38A5 resulted up-regulated in non-responder patients, while high expression levels of EBF1, EDNRA, CCDC18, CCDC186, FYB, MALAT1, MIS18BP1, MYO6, THRAP3 and TOP1, characterized responder DLBCL patients (Figure 1C). Here, MYO6 is linked to diffuse large B-cell lymphoma.